Chemical Name: 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide
Biological ActivityABT 263 is a high affinity inhibitor of Bcl-2 family proteins (Ki values are 0.5 nM, <1 nM and <1 nM in Bcl-xL, Bcl-2 and Bcl-W respectively). ABT 263 induces G1/G0 phase arrest, apoptosis and autophagy in cancer cells in vitro (IC50 = 3.4 - 12 μM). In vivo, ABT 263 displays a synergistic antitumor effect with rituximab and Bortezomib (Cat. No. 7282), Docetaxel (Cat. No. 4056) and Erlotinib (Cat. No. 7194), and inhibits growth of SCLC xenografts when combined with (+)-JQ1 (Cat. No. 4499). ABT 263 also reduces inflammation and viral-induced senescence in SARS-CoV-2 infection in vivo, and clears senescent cells and rejuvenates aging stem cells. Orally bioavailable.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Complete Your Research
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
Reviews for ABT 263
There are currently no reviews for this product. Be the first to review ABT 263 and earn rewards!
Have you used ABT 263?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image